|
|
|
原研机构- |
|
|
最高研发阶段批准上市 |
|
首次获批日期1966-01-01 |
DESENSITIZE-PD: Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Support Dopaminergic Desensitization in Parkinson's Disease
20 patients with idiopathic Parkinson's disease, who are planned to undergo intestinal L-Dopa + entacapone (Lecigon®) treatment will be included into this observational single-armed study. These patient will be observed for hyperdopaminergic complications and neuropsychiatric fluctuations postprocedure at 3, 6 and 12 months.
Study on the incidence of genetic polymorphism in patients with major depression who are treated unsatisfactory with antidepressants - GENADET
100 项与 STADAPHARM GmbH 相关的临床结果
0 项与 STADAPHARM GmbH 相关的专利(医药)
100 项与 STADAPHARM GmbH 相关的药物交易
100 项与 STADAPHARM GmbH 相关的转化医学